Fig. 1. Small molecule glycomimetics inhibit β-GP-induced calcification in human VSMCs. (A & B) Alizarin red staining showing inhibition of calcification by the small molecule glycomimetics (C1-C4) in human VSMC treated with 5 mM β-GP for 21 days (C) C1-C4 reduce β-GP-induced calcium deposition at day 14. Results are mean ± SEM; n = 6-8, and experiments were repeated at least three times independently. ***P<0.001. β-GP, β-glycerophosphate; ns, non-significant.